placebo in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 6 months symptomatic COVIDdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 11.36 [9.02; 14.31]
11.36 [9.02 ; 14.31 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 46,077 NA not evaluable confirmed Covid-19, from 1st dosedetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 5.56 [4.07; 7.58]
5.56 [4.07 ; 7.58 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 42,572 NA not evaluable deathsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 2.00 [0.37; 10.92]
2.00 [0.37 ; 10.92 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable vaccine efficacy from randomization (ITT)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 5.56 [4.07; 7.58]
5.56 [4.07 ; 7.58 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 42,572 NA not evaluable symptomatic Covid-19detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 20.00 [9.95; 40.21]
20.00 [9.95 ; 40.21 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 36,523 NA not evaluable 6 months severe COVID-19detailed results Out of scale BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 30.30 [2.16; 425.32]
30.30 [2.16 ; 425.32 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% NA not evaluable severe COVID-19 occurrencedetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 4.00 [0.18; 89.91]
4.00 [0.18 ; 89.91 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 42,573 NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 2.10 [1.41; 3.14]
2.10 [1.41 ; 3.14 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,355 NA not evaluable related AE (TRAE)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.20 [0.19; 0.22]
0.20 [0.19 ; 0.22 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable related SAE (TRSAE)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable serious adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.88 [0.68; 1.14]
0.88 [0.68 ; 1.14 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.38 [0.36; 0.40]
0.38 [0.36 ; 0.40 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable life-threatening SAEdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1.09 [0.61; 1.98]
1.09 [0.61 ; 1.98 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable severe adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.58 [0.47; 0.71]
0.58 [0.47 ; 0.71 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable appendicitisdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.50 [0.15; 1.66]
0.50 [0.15 ; 1.66 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,448 NA not evaluable Bell's palsydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.13 [0.01; 2.37]
0.13 [0.01 ; 2.37 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 37,586 NA not evaluable hypersensitivity, all termsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.46 [0.18; 1.21]
0.46 [0.18 ; 1.21 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,252 NA not evaluable immediate allergic reactiondetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1.00 [0.02; 50.38]
1.00 [0.02 ; 50.38 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 43,448 NA not evaluable lymphadenopathy, anydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.09 [0.04; 0.22]
0.09 [0.04 ; 0.22 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 37,586 NA not evaluable musculoskeletal and connective tissue disorders, anydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.27 [0.24; 0.31]
0.27 [0.24 ; 0.31 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 37,586 NA not evaluable local adverse reaction, any, dose 1detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.04 [0.04; 0.05]
0.04 [0.04 ; 0.05 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 8,183 NA not evaluable local adverse reaction, any, dose 2detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.04 [0.04; 0.05]
0.04 [0.04 ; 0.05 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 7,507 NA not evaluable systemic adverse reaction, any, dose 1detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.61 [0.56; 0.67]
0.61 [0.56 ; 0.67 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 8,183 NA not evaluable systemic adverse reaction, any, dose 2detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 0.22 [0.20; 0.24]
0.22 [0.20 ; 0.24 ] BNT162b2 phase 3 (C4591001, Polack), 2020 (REV) 1 0% 7,507 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-20 05:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 650
- roots T: 650